An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?

World Journal of Urology

Volumn 33, Issue 11, 2015, Pages 1677-1687

  Feletto, E ^a   Bang, A ^a   Cole Clark, D ^b   Chalasani, V ^c,d   Rasiah, K ^d,e   Smith, D P ^a,f  

^a CANCER RESEARCH DIVISION   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Northern Sydney Local Health District ^*  (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^f GRIFFITH UNIVERSITY   (Australia)

Author keywords

Australia; Canada; England; Mortality; Prostatic neoplasms; USA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; AUSTRALIA; BLOOD; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; EARLY CANCER DIAGNOSIS; ENGLAND; HUMAN; INCIDENCE; MALE; MULTICENTER STUDY; PROCEDURES; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SURVIVAL RATE; TRENDS; UNITED STATES;

AGE DISTRIBUTION; AGED; AUSTRALIA; CANADA; EARLY DETECTION OF CANCER; ENGLAND; HUMANS; INCIDENCE; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 84945460245     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-015-1514-7     Document Type: Article

References (59)

1. Fontes F, Severo M, Castro C et al (2013) Model-based patterns in prostate cancer mortality worldwide. Br J Cancer 108:2354–2366. doi:10.1038/bjc.2013.217
2. Australian Institute of Health and Welfare (2012) Cancer in Australia: an overview. Australian Institute of Health and Welfare, Canberra
3. Andriole GL, Crawford ED, Grubb RL et al (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 Years of Follow-up. J Natl Cancer Inst 104:125–132. doi:10.1093/jnci/djr500
4. Bray F, Lortet-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46:3040–3052. doi:10.1016/j.ejca.2010.09.013
5. Haines IE, Miklos GLG (2013) Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. J Natl Cancer Inst 105:1534–1539. doi:10.1093/jnci/djt248
6. Chowdhury S, Burbridge S, Harper P (2007) Chemotherapy for the treatment of hormone-refractory prostate cancer. J Clin Pract 61:2064–2070. doi:10.1111/j.1742-1241.2007.01551.x
7. Beaulac J, Fry R, Onysko J (2006) Lifetime and recent prostate specific antigen (PSA) screening of men for prostate cancer in Canada. Can J Public Health 97:171–176
8. Williams N, Hughes L, Turner E et al (2011) Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int 108:1402–1408. doi:10.1111/j.1464-410X.2011.10163.x
9. Melia J, Moss S, Johns L, Contributors in the participating laboratories (2004) Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 94:51–56. doi:10.1111/j.1464-4096.2004.04832.x
10. National Cancer Institute (2012) Age groups—standard populations—SEER datasets. Surveillance, epidemiology, and end results program. http://www.seer.cancer.gov/stdpopulations/stdpop.19ages.html. Accessed 26 Mar 2014
11. National Cancer Institute (2013) Joinpoint help. National Cancer Institute, Bethesda
12. Sitas F, Gibberd A, Kahn C et al (2013) Cancer incidence and mortality in people aged less than 75 years: changes in Australia over the period 1987–2007. Cancer Epidemiol 37:780–787. doi:10.1016/j.canep.2013.09.010
13. Ferlay J, Soerjomataram I, Ervik M, et al (2013) GLOBOCAN 2012 v1.0. In: Cancer Incid. Mortal. Worldw. IARC CancerBase No 11 Internet Lyon Fr. International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 17 Dec 2013
14. Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J (2013) Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol 64:703–709. doi:10.1016/j.eururo.2013.05.024
15. Schröder FH (2012) Landmarks in prostate cancer screening. BJU Int 110(Suppl 1):3–7. doi:10.1111/j.1464-410X.2012.011428.x
16. Schröder FH, Hugosson J, Carlsson S et al (2012) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 62:745–752. doi:10.1016/j.eururo.2012.05.068
17. Schröder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035. doi:10.1016/S0140-6736(14)60525-0
18. Moyer VA (2012) Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med 157:120–134. doi:10.7326/0003-4819-157-2-201207170-00459
19. Hsing AW, Tsao L, Devesa SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85:60–67. doi:10.1002/(SICI)1097-0215(20000101)85:1<60:AID-IJC11>3.0.CO;2-B
20. Public Health England (2010) Prostate cancer. UK screening portal UK National Screening Committee. http://www.screening.nhs.uk/prostatecancer. Accessed 16 Dec 2013
21. Public Health England (2012) The UK NSC recommendation on prostate cancer screening/PSA testing in men over the age of 50. UK Screening Portal UK National Screening Committee. http://www.screening.nhs.uk/prostatecancer. Accessed 22 Dec 2014
22. Izawa JI, Klotz L, Siemens R et al (2011) Prostate cancer screening: canadian guidelines 2011. Canadian Urological Association, Dorval
23. Prostate Cancer Foundation of Australia, PSA Testing Guidelines Expert Advisory Panel (2014) Draft clinical practice guidelines PSA testing and early management of test-detected prostate cancer. http://wiki.cancer.org.au/australia/Guidelines:PSA_Testing
24. Gorday W, Sadrzadeh H, de Koning L, Naugler C (2014) Association of sociodemographic factors and prostate-specific antigen (PSA) testing. Clin Biochem 47:164–169. doi:10.1016/j.clinbiochem.2014.08.006
25. Ranasinghe WKB, Kim SP, Lawrentschuk N et al (2014) Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia. BJU Int 113:77–83. doi:10.1111/bju.12354
26. Sirovich BE, Schwartz LM, Woloshin S (2003) Screening men for prostate and colorectal cancer in the united states: does practice reflect the evidence? JAMA 289:1414–1420. doi:10.1001/jama.289.11.1414
27. Lowe A, Bennett M, Badenoch S (2012) Research, awareness, support: ten years of progress in prostate cancer. Prostate Cancer Foundation of Australia, Sydney
28. Aslani A, Minnillo BJ, Johnson B et al (2014) The impact of recent screening recommendations on prostate cancer screening in a large health care system. J Urol 191:1737–1742. doi:10.1016/j.juro.2013.12.010
29. Cohn JA, Wang CE, Lakeman JC et al (2014) Primary care physician PSA screening practices before and after the final US Preventive Services Task Force recommendation. Urol Oncol Semin Orig Investig. 32:41.e23–41.e30. doi: 10.1016/j.urolonc.2013.04.013
30. Oliver SE, Gunnell D, Donovan JL (2000) Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 355:1788–1789. doi:10.1016/S0140-6736(00)02269-8
31. Kachuri L, De P, Ellison L et al (2013) Cancer incidence, mortality and survival trends in Canada, 1970–2007. Chronic Dis Inj Can 33:69–80
32. Ilic D, O’Connor D, Green S, Wilt TJ (2011) Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 107:882–891. doi:10.1111/j.1464-410X.2010.10032.x
33. Brewster D, Fraser L, Harris V, Black R (2000) Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int 85:463–473. doi:10.1046/j.1464-410x.2000.00487.x
34. Penson DF, Albertsen PC, Nelson PS et al (2001) Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 93:1822–1823. doi:10.1093/jnci/93.23.1822
35. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095–2101. doi:10.1001/jama.293.17.2095
36. Duncan ME, Goldacre MJ (2011) Mortality trends for benign prostatic hyperplasia and prostate cancer in English populations 1979–2006. BJU Int 107:40–45. doi:10.1111/j.1464-410X.2010.09487.x
37. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90:162–173. doi:10.1046/j.1464-410X.2002.2822.x
38. Collin SM, Martin RM, Metcalfe C et al (2008) Prostate-cancer mortality in the USA and UK in 1975–2004: an ecological study. Lancet Oncol 9:445–452. doi:10.1016/S1470-2045(08)70104-9
39. Bill-Axelson A, Holmberg L, Ruutu M et al (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352:1977–1984. doi:10.1056/NEJMoa043739
40. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.1056/NEJMoa1113162
41. Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123. doi:10.1200/JCO.2009.26.0133
42. Evans SM, Millar JL, Davis ID et al (2013) Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust 198:540–545. doi:10.5694/mja12.11241
43. Fairley L, Baker M, Whiteway J et al (2009) Trends in non-metastatic prostate cancer management in the Northern and Yorkshire region of England, 2000–2006. Br J Cancer 101:1839–1845. doi:10.1038/sj.bjc.6605424
44. Sachdeva A, van der Meulen J, Emberton M, Cathcart P (2014) Comparison of radical treatment and mortality in patients with non-metastatic prostate cancer in England and USA. BJU Int 113:11. doi:10.1111/bju.12759
45. Peters SM, Jovell AJ, García-Altes A, Serra-Prat M (2001) Screening and clinical management of prostate cancer. A cross-national comparison. Int J Technol Assess Health Care 17:215–221
46. Binder J, Bräutigam R, Jonas D, Bentas W (2004) Robotic surgery in urology: fact or fantasy? BJU Int 94:1183–1187. doi:10.1046/j.1464-410x.2004.05130.x
47. Duthie J, Landau A, O’Connor K et al (2013) Growth trends and adoption of robotic-assisted surgery across Australia and New Zealand. BJU Int 111:20
48. Sandoval Salinas C, González Rangel AL, Cataño Cataño JG et al (2013) Efficacy of robotic-assisted prostatectomy in localized prostate cancer: a systematic review of clinical trials. Adv Urol 2013:105651. doi:10.1155/2013/105651
49. Porpiglia F, Morra I, Lucci Chiarissi M et al (2013) Randomised controlled trial comparing laparoscopic and robot-assisted radical prostatectomy. Eur Urol 63:606–614. doi:10.1016/j.eururo.2012.07.007
50. Thompson J, Lawrentschuk N, Frydenberg M et al (2013) The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int 112(Suppl 2):6–20. doi:10.1111/bju.12381
51. Smith D, Armstrong B (1998) Prostate-specific antigen testing in Australia and association with prostate cancer incidence in New South Wales. Med J Aust 169:17–20
52. Evans SM, Millar JL, Wood JM et al (2013) The prostate cancer registry: monitoring patterns and quality of care for men diagnosed with prostate cancer. BJU Int 111:E158–E166. doi:10.1111/j.1464-410X.2012.11530.x
53. Stattin P, Carlsson S, Holmström B et al (2014) Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst 106:dju007. doi: 10.1093/jnci/dju007
54. Warde P, Mason M, Ding K et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378:2104–2111. doi:10.1016/S0140-6736(11)61095-7
55. Widmark A, Klepp O, Solberg A et al (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373:301–308. doi:10.1016/S0140-6736(08)61815-2
56. Lissbrant IF, Garmo H, Widmark A, Stattin P (2013) Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol Stockh Swed 52:1593–1601. doi:10.3109/0284186X.2013.770164
57. McDavid K, Lee J, Fulton JP et al (2004) Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep 119:174–186
58. Nair-Shalliker V, Smith DP, Egger S et al (2013) The association of ultraviolet radiation-B (305 nm), season of diagnosis, and latitude on the survival outcome of prostate cancer in the high UV environment of Australia. Cancer Causes Control 24:2005–2011. doi:10.1007/s10552-013-0277-y
59. Australian Institute of Health and Welfare (2013) Prostate cancer in Australia. AIHW, Canberra